[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cutaneous-lupus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cutaneous-lupus":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,51,79,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100562149","identification-of-cutaneous-and-blood-biomarkers-predictive-of-response-to-systemic-treatments-during-chronic-inflammatory-skin-diseases-100562149",false,"NCT06599411","Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases","Identification Des Marqueurs Biologiques cutanés et Sanguins prédictifs de réponse Aux Traitements systémiques au Cours Des Maladies cutanées Inflammatoires Chroniques","ImmuneSkinBank","Inclusion Criteria:\n\nPatients:\n\n* Age\\>18 years\n* Informed consent signed by the patient\n* Diagnosis of moderate to severe chronic inflammatory skin disease (IGA score 3 or 4) including: atopic dermatitis, psoriasis, hidradenitis suppurativa, lichen planus, cutaneous lupus, dermatomyositis, cutaneous scleroderma (=morphea), neutrophilic dermatosis, cutaneous granulomatosis, cutaneaous vasculitis, autoimmune bullous dermatosis\n* Or diagnosis of active leprosy (tuberculoid, lepromatous, reversion type 1, reversion type 2, hypersensitivity type 3), excluding pure neurological leprosy. Classification into 5 stages according to the Ridley and Jopling classification \\[1\\], Reversion reaction (type 1 reaction) and leprous erythema nodosum (type 2 reaction).\n\nHealthy controls :\n\n* Age\\>18 years\n* Plastic surgery patients who have had any type of surgery resulting in healthy skin remnants\n* Informed consent signed by the patient\n* Absence of known cutaneous inflammatory disease.\n\nExclusion Criteria:\n\n* Under guardianship or curatorship\n* Pregnant or breastfeeding woman\n* Lack of affiliation with a social security system\n* Current systemic treatment with immunosupressant (including corticosteroid therapy) or an immunomodulator or received within the last 3 months.",true,"ALL","18 Years",{"count":21,"type":22},830,"ESTIMATED","OBSERVATIONAL","Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable. The discovery of prognosis factors will help to precisely guide the treatment regimen and its intensification based on individual markers. The identification of new therapeutic targets is essential to develop new innovative treatments for inflammatory skin diseases.\n\nThe main objective is to identify new cellular or molecular prognostic factors associated with treatment response at 1 year in inflammatory skin diseases.\n\nThe secondary objectives are a better understanding of the pathophysiology of chronic inflammatory skin diseases, the identification of new cellular, molecular and microbiological prognostic factors associated with the clinical state after 10 years of evolution and the identification of prognostic markers of drug toxicity.",[26,27,28,29,30,31,32,33,34,35,36,37],"Atopic Dermatitis","Psoriasis","Hidradenitis Suppurativa","Lichen Planus","Cutaneous Lupus","Dermatomyositis","Cutaneaous Scleroderma","Neutrophilic Dermatosis","Cutaneous Granulomatosis","Active Leprosy","Autoimmune Bullous Dermatosis","Cutaneous Vasculitis","RECRUITING","2026-06-10",{"date":41,"type":42},"2026-06-12","ACTUAL",{"date":44,"type":42},"2025-10-20",{"date":46,"type":22},"2045-10-20",{"name":48,"class":49},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":17,"sex":58,"minAge":4,"maxAge":4,"enrollmentInfo":59,"targetDuration":61,"studyType":23,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":50},"100307028","maternal-autoimmune-disease-research-alliance-madra-registry-100307028","NCT03276923","Maternal Autoimmune Disease Research Alliance (MADRA) Registry","MADRA","Inclusion Criteria:\n\n* Desire for pregnancy within 6 months or currently pregnant\n* Women with systemic autoimmune disease, including:\n* Lupus (systemic lupus erythematosus or cutaneous lupus)\n* Antiphospholipid Syndrome or positive antiphospholipid antibodies\n* Rheumatoid Arthritis\n* Scleroderma (systemic sclerosis)\n* Sjogren's Syndrome\n* Inflammatory Arthritis (including Psoriatic Arthritis and Ankylosing Spondylitis)\n* Undifferentiated Connective Tissue Disease (UCTD)\n* Vasculitis\n* Myositis (Polymyositis or Dermatomyositis)\n* Positive Ro\u002FSSA or La\u002FSSB antibodies\n\nExclusion Criteria:\n\n* Unable to speak English\n* Unable to provide informed consent\n* Unable to travel to Duke University for follow-up visits","FEMALE",{"count":60,"type":22},1000,"100 Years","This multi-site registry, centered at Duke University, will enroll pregnant women with autoimmune and rheumatologic diseases.\n\nThe main goal of MADRA is to identify ways to improve the health of women with rheumatic diseases and their babies during pregnancy.\n\nPrior studies demonstrate the importance of increase inflammation prior to and during pregnancy on these outcomes. The future research will seek to better define these risk factors and to identify ways to may improve them.",[64,65,66,30,67,68,69],"Autoimmune Diseases","Pregnancy Related","Systemic Lupus Erythematosus","Rheumatoid Arthritis","Sjogren's Syndrome","Scleroderma","2026-01-06",{"date":72,"type":42},"2026-01-08",{"date":74,"type":42},"2018-01-01",{"date":76,"type":22},"2027-01-01",{"name":78,"class":49},"Duke University",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":50},"100096160","duke-lupus-registry-100096160","NCT00512694","Duke Lupus Registry","Inclusion Criteria:\n\n* Diagnosis of Systemic Lupus Erythematosus or Cutaneous Lupus\n* Patient of a rheumatologist at Duke University Medical Center\n\nExclusion Criteria:\n\n* Inability to travel to Duke for follow-up visits\n* Inability to speak English\n* Not able to provide informed consent",{"count":60,"type":22},"Lupus is a systemic autoimmune disease that can present with many varied symptoms, including joint pain, fevers, kidney disease, and rashes. Lupus can affect anyone, but it is most common in younger women.\n\nThe Duke Lupus Registry will collect information and blood samples from patients with lupus (systemic lupus erythematosus or cutaneous lupus) seen in the Duke Rheumatology clinics. The goal of this Registry is to understand how lupus changes over time so that we can improve the treatment of patients with lupus.",[66,30],[89,66,30],"Lupus",{"date":72,"type":42},{"date":92,"type":4},"2007-07",{"date":94,"type":22},"2028-06",{"name":78,"class":49},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":17,"sex":18,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":105,"conditions":106,"keywords":110,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":50},"100510571","determinants-of-chronic-inflammatory-skin-disease-trajectories-100510571","NCT05928169","Determinants of Chronic Inflammatory Skin Disease Trajectories","Inclusion Criteria:\n\n* dermatologist-diagnosed inflammatory skin disease\n* informed consent\n\nExclusion Criteria:\n\n* subject and\u002For the legal guardians are not able to give written informed consent\n* pregnant and breastfeeding women\n* concurrent participation in a clinical trial\n* use of systemic immunosuppressive therapy or phototherapy during the last 4 weeks or receipt of biologics therapy (e.g. dupilumab, tralokinumab) within the last 3 months\n* treatment of the target skin areas with topical corticosteroids, calcineurin inhibitors or emollients 24 hours before sample collection","0 Years","80 Years",{"count":60,"type":22},"Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation, clinical features and course are also largely unknown. There are currently no reliable markers that could predict or delineate patient subgroups to support patient management. The aim of this project is to identify clinical and molecular factors that correlate with disease, disease subtypes and progression through in-depth long-term clinical characterization of patients with chronic inflammatory skin diseases and examination of individual biomaterials.",[26,27,29,107,28,108,30,109],"Alopecia Areata","Prurigo Nodularis","Rosacea",[111],"Inflammatory Skin Diseases","2025-07-17",{"date":114,"type":42},"2025-07-22",{"date":116,"type":42},"2023-05-01",{"date":118,"type":22},"2032-12-31",{"name":120,"class":49},"University Hospital Schleswig-Holstein"]